MA39390B2 - Thérapie génique pour le traitement de la rétinite pigmentaire - Google Patents

Thérapie génique pour le traitement de la rétinite pigmentaire

Info

Publication number
MA39390B2
MA39390B2 MA39390A MA39390A MA39390B2 MA 39390 B2 MA39390 B2 MA 39390B2 MA 39390 A MA39390 A MA 39390A MA 39390 A MA39390 A MA 39390A MA 39390 B2 MA39390 B2 MA 39390B2
Authority
MA
Morocco
Prior art keywords
treatment
retinitis pigmentosa
gene therapy
viral particles
particles
Prior art date
Application number
MA39390A
Other languages
English (en)
Other versions
MA39390A1 (fr
Inventor
Catherine O'riordan
Matthew Adamowicz
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52829343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39390(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA39390A1 publication Critical patent/MA39390A1/fr
Publication of MA39390B2 publication Critical patent/MA39390B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

La présente invention concerne des procédés pour le traitement de la rétinite pigmentaire au moyen de particules d'aav codant mir -708. Dans un aspect de l'invention, des particules virales sont administrées dans l'œil d'un sujet humain, par exemple, par injection sous-rétinienne. Des particules virales comprenant des capsides d'aav5 ou des mutants de ceux-ci sont envisagées.
MA39390A 2014-03-21 2015-03-20 Thérapie génique pour le traitement de la rétinite pigmentaire MA39390B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461969027P 2014-03-21 2014-03-21
PCT/US2015/021896 WO2015143418A2 (fr) 2014-03-21 2015-03-20 Thérapie génique pour le traitement de la rétinite pigmentaire

Publications (2)

Publication Number Publication Date
MA39390A1 MA39390A1 (fr) 2017-12-29
MA39390B2 true MA39390B2 (fr) 2022-04-29

Family

ID=52829343

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39390A MA39390B2 (fr) 2014-03-21 2015-03-20 Thérapie génique pour le traitement de la rétinite pigmentaire

Country Status (36)

Country Link
US (3) US10383953B2 (fr)
EP (3) EP3119437B1 (fr)
JP (3) JP6669664B2 (fr)
KR (2) KR20160127832A (fr)
CN (2) CN115252823A (fr)
AR (1) AR099837A1 (fr)
AU (2) AU2015230942B2 (fr)
CA (1) CA2943185A1 (fr)
CL (1) CL2016002333A1 (fr)
CR (1) CR20160480A (fr)
DK (2) DK3628334T3 (fr)
DO (1) DOP2016000237A (fr)
EA (1) EA201691891A1 (fr)
EC (1) ECSP16083000A (fr)
ES (2) ES2760263T3 (fr)
FI (1) FI3628334T3 (fr)
HR (2) HRP20231077T1 (fr)
HU (2) HUE046454T2 (fr)
IL (3) IL247543B (fr)
LT (2) LT3119437T (fr)
MA (1) MA39390B2 (fr)
MX (2) MX2016012201A (fr)
MY (1) MY190726A (fr)
NZ (1) NZ724622A (fr)
PE (1) PE20161252A1 (fr)
PH (1) PH12016501684A1 (fr)
PL (2) PL3119437T3 (fr)
PT (2) PT3628334T (fr)
RS (2) RS59634B1 (fr)
SG (3) SG10201912968WA (fr)
SI (2) SI3119437T1 (fr)
TW (2) TWI706789B (fr)
UA (1) UA120050C2 (fr)
UY (1) UY36044A (fr)
WO (1) WO2015143418A2 (fr)
ZA (1) ZA201605924B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046454T2 (hu) 2014-03-21 2020-03-30 Genzyme Corp Retinitis pigmentosa génterápia
WO2016130589A2 (fr) 2015-02-10 2016-08-18 Genzyme Corporation Variant d'arni
US10994026B2 (en) 2015-12-03 2021-05-04 Friedrich Miescher Institute For Biomedical Research SynP160, a promoter for the specific expression of genes in rod photoreceptors
JP7075341B2 (ja) 2015-12-03 2022-05-25 フリードリッヒ ミーシェー インスティトゥート フォー バイオメディカル リサーチ ＳｙｎＰ１６２、桿体光受容器における遺伝子の特異的発現のためのプロモーター
WO2017093566A1 (fr) 2015-12-04 2017-06-08 Universite Pierre Et Marie Curie (Paris 6) Promoteurs et leurs utilisations
US11118185B2 (en) * 2016-03-01 2021-09-14 University Of Florida Research Foundation, Incorporated AAV vectors for treatment of dominant retinitis pigmentosa
BR112019000057A2 (pt) * 2016-07-05 2019-04-02 The Johns Hopkins University composições e métodos com base em crispr/cas9 para o tratamento de degeneração de retina
BR112020005569A2 (pt) * 2017-09-22 2020-10-06 Genzyme Corporation rna de interferência (rnai) variante
KR20200057051A (ko) * 2017-09-27 2020-05-25 시질론 테라퓨틱스, 인크. 활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소
CN107961380B (zh) * 2017-11-23 2020-05-05 清华大学 试剂在制备药物中的用途、筛选药物的方法以及药物组合物
EP4186921A1 (fr) * 2018-03-23 2023-05-31 The Trustees of Columbia University in the City of New York Édition de gènes pour maladies autosomiques dominantes
CA3102095A1 (fr) * 2018-06-01 2019-12-05 University Of Florida Research Foundation, Incorporated Compositions et methodes pour le traitement de la retinite pigmentaire dominante
CN111518813B (zh) * 2019-02-03 2023-04-28 武汉纽福斯生物科技有限公司 视紫红质的编码序列、其表达载体构建及其应用
SG11202109554XA (en) * 2019-03-04 2021-09-29 Univ Pennsylvania Neuroprotective gene therapy targeting the akt pathway
CN114206393A (zh) * 2019-03-21 2022-03-18 Ptc医疗公司 用于治疗天使综合征的载体和方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262529A (en) * 1990-01-24 1993-11-16 President And Fellows Of Harvard College Diagnosis of hereditary retinal degenerative diseases
US5985583A (en) * 1992-06-23 1999-11-16 Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of gonadotropin-releasing hormone receptor
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
JP4827353B2 (ja) 1999-08-09 2011-11-30 ターゲティッド ジェネティクス コーポレイション 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大
AU2001269723B9 (en) 2000-06-01 2006-11-16 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
BRPI0214119B8 (pt) 2001-11-13 2021-05-25 Univ Pennsylvania vírus adenoassociado recombinante, método de geração do referido vírus e composição compreendendo o referido vírus
CA2553976C (fr) * 2004-01-22 2013-09-24 Dnavec Research Inc. Procede de production d'un vecteur de virus a arn a brin negatif a l'aide d'un promoteur hybride contenant un activateur de cytomegalovirus et un promoteur de .beta.-actine aviaire
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
WO2006119432A2 (fr) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, clonage, et caracterisation de nouveaux serotypes de virus adeno-associes (avv)
EP2007795B1 (fr) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Protéines de capsides aav
WO2008125846A2 (fr) * 2007-04-12 2008-10-23 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Suppression et remplacement génétique
US20090214478A1 (en) * 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
US9217155B2 (en) * 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US8734809B2 (en) * 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
CN102573856B (zh) * 2009-09-10 2016-10-26 弗莱明·韦林 用于制备微小rna 的方法及其治疗性应用
BR112012018899A2 (pt) * 2010-01-28 2015-09-15 Philadelphia Children Hospital "método para purificar partículas de vetor de vírus adeno-associado."
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
WO2012057363A1 (fr) * 2010-10-27 2012-05-03 学校法人自治医科大学 Virions de virus adéno-associé pour le transfert de gènes dans des cellules neuronales
EP2675902B1 (fr) 2011-02-17 2019-03-27 The Trustees Of The University Of Pennsylvania Compositions et méthodes pour modifier la specificite au tissus et ameliorer le transfert de gene a mediation par aav9
JP5884152B2 (ja) 2011-07-29 2016-03-15 シャープ株式会社 基地局、端末、通信システムおよび通信方法
ITRM20110685A1 (it) * 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
CN104520428B (zh) * 2012-02-17 2018-09-21 费城儿童医院 将基因转移到细胞、器官和组织的aav载体组合物和方法
US9192651B2 (en) * 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
LT2800811T (lt) * 2012-05-25 2017-09-11 The Regents Of The University Of California Būdai ir kompozicijos, skirti tikslinės dnr modifikavimui, panaudojant adresuotą rnr, ir transkripcijos moduliavimui, panaudojant adresuotą rnr
AU2013287281B2 (en) 2012-07-11 2018-04-26 The Trustees Of The University Of Pennsylvania AAV-mediated gene therapy for RPGR x-linked retinal degeneration
EP2912177A1 (fr) * 2012-10-23 2015-09-02 Cornell University Traitement du cancer du sein métastatique
BR112016007176A2 (pt) 2013-10-04 2018-01-23 Merck Sharp & Dohme conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete
HUE046454T2 (hu) * 2014-03-21 2020-03-30 Genzyme Corp Retinitis pigmentosa génterápia

Also Published As

Publication number Publication date
EA201691891A1 (ru) 2017-01-30
AU2015230942B2 (en) 2020-11-19
IL247543B (en) 2020-07-30
IL284741B2 (en) 2023-02-01
PT3628334T (pt) 2023-09-26
MY190726A (en) 2022-05-12
UA120050C2 (uk) 2019-09-25
CN106456660B (zh) 2022-05-31
AR099837A1 (es) 2016-08-24
SG10201912968WA (en) 2020-02-27
NZ724622A (en) 2022-05-27
US20220054657A1 (en) 2022-02-24
PH12016501684A1 (en) 2016-10-03
PL3119437T3 (pl) 2020-04-30
PE20161252A1 (es) 2016-11-30
ECSP16083000A (es) 2017-02-24
RS64611B1 (sr) 2023-10-31
CL2016002333A1 (es) 2017-05-26
IL247543A0 (en) 2016-11-30
HRP20192141T1 (hr) 2020-02-21
FI3628334T3 (fi) 2023-09-15
HUE046454T2 (hu) 2020-03-30
IL275918A (en) 2020-08-31
SG11201607005UA (en) 2016-09-29
SI3119437T1 (sl) 2020-01-31
DK3119437T3 (da) 2019-12-09
PT3119437T (pt) 2019-12-12
SI3628334T1 (sl) 2023-11-30
IL284741B (en) 2022-10-01
US10383953B2 (en) 2019-08-20
CN115252823A (zh) 2022-11-01
ES2760263T3 (es) 2020-05-13
EP4345165A2 (fr) 2024-04-03
AU2021200988A1 (en) 2021-03-11
TWI780401B (zh) 2022-10-11
KR20160127832A (ko) 2016-11-04
BR112016021017A2 (pt) 2017-10-03
LT3119437T (lt) 2019-12-27
TW202021627A (zh) 2020-06-16
UY36044A (es) 2015-10-30
TWI706789B (zh) 2020-10-11
MX2016012201A (es) 2017-01-19
CN106456660A (zh) 2017-02-22
WO2015143418A3 (fr) 2015-11-19
PL3628334T3 (pl) 2023-12-18
IL275918B (en) 2021-07-29
AU2015230942A1 (en) 2016-10-13
JP2020059737A (ja) 2020-04-16
ES2957840T3 (es) 2024-01-26
HUE063460T2 (hu) 2024-01-28
EP3119437A2 (fr) 2017-01-25
US20200046851A1 (en) 2020-02-13
MA39390A1 (fr) 2017-12-29
US11103598B2 (en) 2021-08-31
US20170173183A1 (en) 2017-06-22
TW201622752A (zh) 2016-07-01
EP3628334B1 (fr) 2023-06-28
KR20230006039A (ko) 2023-01-10
RS59634B1 (sr) 2020-01-31
WO2015143418A2 (fr) 2015-09-24
JP2017509632A (ja) 2017-04-06
CA2943185A1 (fr) 2015-09-24
EP3119437B1 (fr) 2019-09-04
HRP20231077T1 (hr) 2023-12-22
ZA201605924B (en) 2017-09-27
JP7048563B2 (ja) 2022-04-05
MX2020010694A (es) 2020-11-06
DK3628334T3 (da) 2023-10-02
DOP2016000237A (es) 2016-10-16
LT3628334T (lt) 2023-09-25
EP3628334A1 (fr) 2020-04-01
IL284741A (en) 2021-08-31
CR20160480A (es) 2016-12-14
NZ762841A (en) 2023-11-24
SG10201808218YA (en) 2018-10-30
JP6669664B2 (ja) 2020-03-18
JP2022084810A (ja) 2022-06-07

Similar Documents

Publication Publication Date Title
MA39390B2 (fr) Thérapie génique pour le traitement de la rétinite pigmentaire
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
RU2017119647A (ru) Способ лечения болезней глаз
MA38406A1 (fr) Virus de la maladie de newcastle et leurs utilisations
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX2019004280A (es) Organonitro-sulfoalquilo y compuestos relacionados y composiciones farmacéuticas para uso en medicina.
WO2017106899A3 (fr) Méthodes thérapeutiques utilisant les érythrocytes
ZA201701881B (en) Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
EP4279127A3 (fr) Facteur de différentiation de croissance 15 en tant que biomarqueur de metformine
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
EA201790563A1 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX2017012397A (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
MX2020010477A (es) Composiciones y metodos para el tratamiento de la distrofia macular.
EA202191115A1 (ru) Новые пиридазины
MX2021006253A (es) Terapias génicas para enfermedad neurodegenerativa.
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
MX2021008941A (es) Moduladores gpr35.
PH12016501347A1 (en) Filters for infusion sets
EA201791442A1 (ru) Способы лечения гематологических нарушений, солидных опухолей или инфекционных заболеваний с применением естественных клеток-киллеров
EA202191927A1 (ru) Модуляторы gpr35
TN2019000238A1 (en) Methods for treating complement-mediated diseases and disorders